ROR1 as a novel therapeutic target for EGFR-mutant non-small-cell lung cancer patients with the EGFR T790M mutation

BACKGROUND: Activation of bypass signaling pathways, impairment of apoptosis and mutation of epidermal growth factor receptor (EGFR) to a drug-resistant state are well known mechanisms of resistance to single-agent erlotinib therapy in non-small-cell lung cancer (NSCLC) driven by EGFR mutations. Orp...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Transl Lung Cancer Res
Asıl Yazarlar: Karachaliou, Niki, Gimenez-Capitan, Ana, Drozdowskyj, Ana, Viteri, Santiago, Moran, Teresa, Carcereny, Enric, Massuti, Bartomeu, Vergnenegre, Alain, de Marinis, Filippo, Molina, Miguel Angel, Teixido, Cristina, Rosell, Rafael
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Pioneer Bioscience Publishing Company 2014
Konular:
Original Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4367691/
https://ncbi.nlm.nih.gov/pubmed/25806291
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3978/j.issn.2218-6751.2014.03.02
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller